External models of R&D innovation are the rage in Pharma today, as they should be – the future of our industry depends on a great deal more rather than less collaboration.
In a very healthy way, lots of experiments are being done across the ecosystem and the final scorecard for what worked and what didn’t is years from being tallied up; however, the early biomarkers are positive and it’s a widely-held belief that a critical element of exceptional R&D organizations in the future will be creative BD engagement. In short, great BD and R&D are becoming synonymous with each other.